News and analysis on disease research and diagnostics.
PanCAN has invested $25 million in the study, which will screen blood samples from new-onset diabetes patients for biomarkers associated with pancreatic cancer.
Recent results from the firm's case-control study cohort showed overall sensitivity of about 50 percent but higher performance for a subset of high-mortality cancers.
The company will use the funds to accelerate the clinical development and commercialization of its minimal residual disease detection C2-Intelligence Platform.
The trial will identify patients using NGS and an IHC assay, which Ideaya and Ventana codeveloped to confirm MTAP protein levels.
The French cancer center will use OncoDNA's blood-based next-generation sequencing test, OncoFollow, in its ongoing SCANDARE study.
